focus -WSS

focus

author：hotspot 2025-09-29 19:57:34 - browse：36

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Ebola vaccine can save some who are already sick, per new study

leisure time

WSS

Sanders wants to replace patents with prizes for drug inventions

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Juul documents reveal insider tactics on political lobbying

Abbott's new heart device gets FDA advisory panel nod

Too many hospitalized Covid

focus

focus

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Long Covid research funding gets a major boost from NIH

Drug repurposing or repositioning? The language matters

Mystery swirls around US soldier who entered North Korea days ago, officials say

Apple is now the first public company to be valued at $3 trillion

Hormonal contraceptives don’t actually treat endometriosis

Wildfire smoke exposes gaps in outdoor worker protections

Caribou posts encouraging results on off

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

A new ‘biological computer' targets cancer while sparing healthy cells

Wikipedia

Judge denies Trump's request for new trial in E. Jean Carroll case

STAT Boddities: What happens to the brain when we get scared?

A new ‘biological computer' targets cancer while sparing healthy cells

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

US jobless claims fall again as labor market continues to flash strength

knowledge

Wikipedia

leisure time

Wikipedia